rs11984453 - CSMD1

Magnitude 4.5 · 1 study on file

Reported associations

• Genome-wide association study of paliperidone efficacy. - Pharmacogenetics and genomics (2017) · Li Q, Wineinger NE, Fu DJ, Libiger O, Alphs L, Savitz A, Gopal S, Cohen N, Schork NJ · PubMed 27846195

  Clinical response to the atypical antipsychotic paliperidone is known to vary among schizophrenic patients. We carried out a genome-wide association study to identify common genetic variants predictive of paliperidone efficacy. We leveraged a collection of 1390 samples from individuals of European ancestry enrolled in 12 clinical studies investigating the efficacy of the extended-release tablet paliperidone ER (n1=490) and the once-monthly injection paliperidone palmitate (n2=550 and n3=350). We carried out a genome-wide association study using a general linear model (GLM) analysis on three separate cohorts, followed by meta-analysis and using a mixed linear model analysis on all samples. The variations in response explained by each single nucleotide polymorphism (hSNP) were estimated. No

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.